Dynasty Wealth Management LLC Invests $525,000 in Gilead Sciences, Inc. $GILD

Dynasty Wealth Management LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 4,280 shares of the biopharmaceutical company’s stock, valued at approximately $525,000.

Several other hedge funds have also modified their holdings of the company. Paulson Wealth Management Inc. raised its holdings in shares of Gilead Sciences by 1.8% during the 4th quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock worth $477,000 after acquiring an additional 67 shares in the last quarter. Essex Financial Services Inc. raised its holdings in shares of Gilead Sciences by 0.9% during the 4th quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock worth $948,000 after acquiring an additional 71 shares in the last quarter. Alpha Cubed Investments LLC raised its holdings in shares of Gilead Sciences by 1.1% during the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock worth $812,000 after acquiring an additional 75 shares in the last quarter. Personal CFO Solutions LLC raised its holdings in shares of Gilead Sciences by 1.7% during the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock worth $561,000 after acquiring an additional 76 shares in the last quarter. Finally, Moss Adams Wealth Advisors LLC raised its holdings in shares of Gilead Sciences by 1.7% during the 4th quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock worth $546,000 after acquiring an additional 76 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the transaction, the chief executive officer owned 617,567 shares of the company’s stock, valued at approximately $81,185,357.82. This represents a 2.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Friday, May 15th. The stock was sold at an average price of $131.29, for a total value of $3,676,120.00. Following the transaction, the insider directly owned 125,779 shares in the company, valued at $16,513,524.91. The trade was a 18.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 68,000 shares of company stock valued at $9,047,570. 0.30% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Performance

GILD stock opened at $128.99 on Thursday. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The business’s fifty day simple moving average is $134.74 and its two-hundred day simple moving average is $134.31. Gilead Sciences, Inc. has a twelve month low of $104.46 and a twelve month high of $157.29. The firm has a market cap of $160.15 billion, a price-to-earnings ratio of 17.57 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. During the same quarter last year, the firm posted $1.81 earnings per share. The business’s revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Analysts predict that Gilead Sciences, Inc. will post -0.79 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio is presently 44.69%.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported positive late-stage Livdelzi data in primary biliary cholangitis, reinforcing the drug’s commercial potential and supporting the company’s liver-disease growth story. Article Title
• Positive Sentiment: Additional coverage highlighted long-term efficacy and safety data for Livdelzi, which could help Gilead expand the drug’s reach in PBC. Article Title Article Title
• Positive Sentiment: Royal Bank of Canada upgraded Gilead from hold to moderate buy, a sign that analyst confidence is improving.
• Positive Sentiment: Cencora said it will support U.S. distribution of Kite’s FDA-approved CAR-T therapies, helping Gilead’s cell-therapy business maintain access and commercialization momentum. Article Title
• Neutral Sentiment: Gilead remains in the spotlight because investors are closely watching the stock and the company’s broader pipeline, but that attention alone does not change fundamentals. Article Title
• Negative Sentiment: CEO Daniel Patrick O’Day sold 15,000 shares under a pre-arranged trading plan, which can still create a modest headwind for sentiment despite being routine. Article Title

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Mizuho upped their price objective on Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a report on Wednesday, February 18th. Royal Bank Of Canada reissued an “overweight” rating and set a $122.00 target price on shares of Gilead Sciences in a research report on Monday. Sanford C. Bernstein reissued an “outperform” rating and set a $160.00 target price on shares of Gilead Sciences in a research report on Wednesday, February 11th. Leerink Partners cut their target price on Gilead Sciences from $148.00 to $146.00 in a research report on Friday, May 8th. Finally, Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a research report on Wednesday, May 20th. Twenty-six analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $156.93.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.